Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
IMMP
IMMP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IMMP News
Immutep's TACTI-004 Trial Reaches 50% Enrollment Milestone
Feb 06 2026
Newsfilter
Immutep's First LAG-3 Antibody Trial Shows Positive Phase I Results
Dec 22 2025
Benzinga
ASX Penny Stocks Highlight: DUG Technology Featured Among Three Key Selections
Dec 15 2025
Yahoo Finance
Immutep Secures Exclusive Eftilagimod Alfa Licensing Deal with Dr. Reddy's for $20M Upfront Payment
Dec 08 2025
Newsfilter
Highlights of ASX Penny Stocks: Immutep and Two Other Notable Selections
Nov 16 2025
Yahoo Finance
EFTISARC-NEO Phase II Trial Achieves Primary Endpoint for Neoadjuvant Efti in Soft Tissue Sarcoma, Findings Revealed at ESMO Congress 2025
Oct 20 2025
Newsfilter
Immutep Provides Update on TACTI-004 (KEYNOTE-F91) Phase III Trial for First-Line Treatment of Non-Small Cell Lung Cancer
Oct 09 2025
Newsfilter
Biotech Stocks Surge in After-Hours Trading Following Trial News, Insider Purchases, and Conference Excitement
Sep 10 2025
NASDAQ.COM
Immutep Gets Positive Feedback From FDA On Late-Stage Clinical Development Of Eftilagimod Alfa
Aug 05 2025
NASDAQ.COM
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo
May 15 2025
Benzinga
Immutep's Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
May 15 2025
Newsfilter
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
May 06 2025
Benzinga
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
Mar 20 2025
Newsfilter
Immutep Ltd (PRRUF) Receives a Buy from Canaccord Genuity
Mar 07 2025
Business Insider
Patient Enrolment Completed for INSIGHT-003
Jan 06 2025
Newsfilter
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
Dec 17 2024
Newsfilter
Show More News
